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Neutralizing antibodies represent a major host defense mechanism against viral infections. In mammals,
passive immunity is provided by neutralizing antibodies passed to the offspring via the placenta or the milk as
immunoglobulin G and secreted immunoglobulin A. With the long-term goal of producing virus-resistant
livestock, we have generated mice carrying transgenes that encode the light and heavy chains of an antibody
that is able to neutralize the neurotropic JHM strain of murine hepatitis virus (MHV-JHM). MHV-JHM
causes acute encephalitis and acute and chronic demyelination in susceptible strains of mice and rats. Trans-
gene expression was targeted to the lactating mammary gland by using the ovine b-lactoglobulin promoter.
Milk from these transgenic mice contained up to 0.7 mg of recombinant antibody/ml. In vitro analysis of milk
derived from different transgenic lines revealed a linear correlation between antibody expression and virus-
neutralizing activity, indicating that the recombinant antibody is the major determinant of MHV-JHM neu-
tralization in murine milk. Offspring of transgenic and control mice were challenged with a lethal dose of
MHV-JHM. Litters suckling nontransgenic dams succumbed to fatal encephalitis, whereas litters suckling
transgenic dams were fully protected against challenge, irrespective of whether they were transgenic. This
demonstrates that a single neutralizing antibody expressed in the milk of transgenic mice is sufficient to
completely protect suckling offspring against MHV-JHM-induced encephalitis.
Coronaviruses are a group of enveloped viruses with a sin-
gle-stranded RNA genome of positive polarity (37). They are
frequently associated with respiratory and gastrointestinal dis-
orders in both animals and humans. Many coronavirus infec-
tions are mild in adult animals, whereas they often cause se-
vere and sometimes lethal diseases in neonates (9, 32). To a
large extent, this is due to the immature immune system of the
newborn host. Maternal antibodies supplied via the placenta
and milk efficiently protect newborn animals against the fatal
consequences of acute coronavirus infections during this crit-
ical phase (14, 15). Cross-fostering experiments have shown
that milk-borne antibodies (immunoglobulin A [IgA] and IgG)
are sufficient to completely protect newborn mice against le-
thal doses of murine hepatitis virus (MHV) (15).
Vaccination against coronavirus infections has been em-
ployed with various degrees of success (23, 25, 36). The vac-
cines are usually highly strain specific (16), but they are also
dependent on specific routes of infection and often short-lived.
Live-virus vaccines are also associated with the danger of in
vivo recombination, leading to novel viruses with increased
pathogenicity.
Neutralizing monoclonal antibodies generated in response
to coronavirus infections have been isolated in many labora-
tories (12, 35, 42), and it has been shown that antibodies which
inhibit virus entry into susceptible cells in vitro can also effec-
tively prevent acute coronavirus-induced disease in vivo (26,
42). Coronavirus infections cause a high mortality only during
a short time period (up to 20 days postpartum in mice), which
largely coincides with the suckling period. We and others (3,
39) have therefore reasoned that the recombinant expression
of neutralizing antibodies in the milk of transgenic animals
may provide an effective strategy to protect animals during this
critical phase. To provide a proof of principle, we have gener-
ated transgenic mice expressing a highly neutralizing monoclo-
nal antibody directed against the neurotropic MHV strain
JHM (MHV-JHM). The recombinant antibody was secret-
ed into the milk at yields of up to 0.7 mg/ml. The biological
activity of the milk-borne antibody was demonstrated by virus
neutralization assays in vitro, and a linear correlation between
antibody expression and neutralization was found. When litters
suckling transgenic dams were infected with a lethal dose of
MHV-JHM, they were completely protected against virus-in-
duced disease, irrespective of whether the newborn mice were
transgenic. These results provide the first example of trans-
gene-mediated lactogenic immunity in vivo.
MATERIALS AND METHODS
DNA cloning. Monoclonal antibody (MAb) A1 was selected for these studies
because it is highly potent with regard to virus neutralization and inhibition of
virus-induced cell-to-cell fusion (42). The isolation and cloning of cDNAs en-
coding the variable regions of MAb A1 have been described previously (21). In
brief, mRNA was isolated from the A1 hybridoma cell line and reverse tran-
scribed. The resulting vk and vg cDNAs were amplified by PCR, using primers
which bind in the framework of the variable regions (21). The variable region-
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encoding cDNAs were subsequently inserted into expression vectors (Lys30-A1H
and Lys17-A1L), providing a signal peptide and human IgG1 constant regions.
The chimeric antibody carrying the human constant regions is easily identified
against the background of murine antibodies in murine milk by immunological
assays. To generate plasmid pBJ41-A1L, the coding region of the chimeric
antibody A1 light chain was excised from plasmid Lys17-A1L (21) as a NcoI-
EcoRI fragment, blunt ended by treatment with Escherichia coli DNA polymer-
ase I, and inserted into plasmid pBJ41 (39) that had been digested with EcoRV
(Fig. 1). To generate the vector pBJ41-A1H, the chimeric antibody A1 heavy
chain coding region was excised from plasmid Lys30-A1H (21) as a blunt-ended
NcoI-EagI fragment and ligated into expression vector pBJ41 that had been
digested with EcoRV (Fig. 1). Expression vector pBJ41 carries 4.3 kb of 59
flanking region and 1.9 kb of 39 flanking region derived from the ovine b-lacto-
globulin (b-LG) gene. The vector also includes the transcriptional initiation site
and polyadenylation signal at the end of exon 7 of the b-LG gene, but it lacks the
b-LG translational initiation codon (Fig. 1). The first initiation codon in the
chimeric mRNA is therefore provided by the inserted A1L or A1H gene se-
quences (Fig. 1).
Animals. Transgenic mice (F1 CBA 3 C57BL/6) were produced by pronuclear
injection at the animal facility of the Roslin Institute as described previously (4,
43). The plasmids pBJ41-A1L and pBJ41-A1H and the genomic b-LG vector
pSS1tgXS (1) were all linearized by digestion with SalI-XbaI and microinjected
at a 1:1:3 ratio. pSS1tgXS carries the entire b-LG coding region, with 4.3 kb of
59 flanking region and 1.9 kb of 39 flanking region. An excess of genomic b-LG
vector over the expression vector biases for increased frequency of transgene
expression (4). Transgenic mice were identified by PCR and Southern blot
analysis of genomic DNA. The pBJ41-A1H transgene was detected by PCR,
using the primers pBJup (59 AGC CTG CCT GTC TCA GCC CT 39) and A1Hsp
(59-TGC ATG TGA TGG ACA GGC-39). The primer pair gives rise to a 264-bp
product. The pBJ41-A1L transgene was detected by Southern blot analysis of
BamHI-digested genomic DNA. The blot was hybridized with a pBJ41-A1L-
specific 281-bp PCR product amplified with the primer pair pBJup and A1Lsp
(59-CTA CTA AGG TTT TTG CAT TA-39), using plasmid DNA as template.
Transgene copy number was determined by Southern blot analysis on liver DNA
from G1 mice. Aliquots (20 mg) of DNA were digested with BamHI, separated
on a 1% agarose gel, and blotted to a nylon membrane. The blot was subse-
quently probed with a 1.6-kb BamHI-SphI fragment of the b-LG promoter which
is present in all three constructs. Eleven transgenic founder mice were generated,
eight of which transmitted the transgenes. These eight lines were used for further
analysis.
The virus challenge experiments were carried out with pathogen-free C57BL/6
(B6) mice obtained from the National Cancer Institute (Bethesda, Md.). These
mice were seronegative for MHV-JHM. Transgenic females were crossed back
with B6 males for five generations, and offspring were screened for the presence
of the transgenes as described above. For cross-fostering experiments, suckling
mice born to B6 females mated with B6 males and transgenic females mated with
B6 males were switched within 24 h of delivery.
Protein analysis. Western blot analyses were done essentially as described
previously (20). The milk of transgenic mice (isolated at peak lactation, day 10
postpartum) was diluted 1:5 with water and centrifuged at 14,000 3 g for 5 min.
Three phases were separated: a layer of fat above an aqueous phase and a pellet.
The aqueous phase containing the whey fraction was isolated, and aliquots were
mixed with reducing and denaturing sample buffer and separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. The electrophoretically sep-
arated proteins were transferred to a nitrocellulose membrane by semidry elec-
troblotting. The constant regions of the chimeric A1 antibody were detected by
using a rabbit anti-human IgG-horseradish peroxidase (HRP)-linked antiserum
(Dianova). The results were quantified by densitometric scanning on a Molecular
Dynamics Densitometer.
Cells and viruses. DBT (delayed brain tumor) cells (24) were cultivated at
37°C in minimum essential medium (Life Technologies) supplemented with 10%
fetal bovine serum (Sigma), nonessential amino acids, glutamine, and antibiotics.
The MHV-JHM strain used for the in vitro experiments was described previously
(35). Virus neutralization was quantified in syncytium focus reduction assays.
MHV-JHM infections lead to extensive cell-to-cell fusion without inducing cy-
tophathic effects in the first 24 h postinfection. However, syncytium formation (as
is the case with plaque formation) indicates the presence of an infection center
and is therefore equivalent to plaque formation in its diagnostic value. In keeping
with the literature, the number of infectious centers is referred to as PFU.
Defatted and diluted milk samples were further diluted in phosphate-buffered
saline. Aliquots (500 ml) of a 1024 dilution of MHV-JHM, equivalent to about 70
PFU of virus, were mixed with 500 ml of different dilutions of milk samples
isolated from transgenic lines or nontransgenic control mice and incubated for
1 h at 37°C. Subsequently, the virus-antibody mixture was added to confluent
DBT cells for 1 h at 37°C. The virus-containing supernatant was then removed.
The cells were washed twice with phosphate-buffered saline, and fresh medium
was added. Foci of syncytium formation were counted after the infected cells
were incubated for 16 h at 37°C. The virus strain used for the in vivo studies was
grown and titers were determined as described previously (31). To determine the
protective efficacy of breast milk-expressed antibody, 10-day-old mice were chal-
lenged by intranasal or intracerebral inoculation, as described previously (31).
Intranasal challenge was done by inoculation of 2 3 104 to 4 3104 PFU of
MHV-JHM. Intracerebral challenge was done by inoculation of 7 3 102 or 7 3
FIG. 1. Schematic representation of the ovine b-LG gene, the ex-
pression vector pBJ41, and the transgene constructs pBJ41-A1H and
pBJ41-A1L. Exons of the b-LG gene and the human IgG genes are
represented by shaded boxes and filled boxes, respectively. Exons en-
coding the heavy chain constant region are marked as 1, H, 2, and 3;
the exon encoding the light chain constant region is marked as Ck. The
inserted variable regions (Vg and Vk) isolated from the A1 mouse
hybridoma cell line are represented as hatched boxes. The mammary
gland-specific expression vector pBJ41 contains sequences from the
first and fifth exons (17 and 8 bp, respectively) and the entire sixth and
seventh exons of the b-LG gene. A linker carrying a singular EcoRV
site was inserted in between the two PvuII sites in exons 1 and 5. a, b,
and c, b-LG translational initiation site, stop codon, and polyadenyl-
ation signal, respectively; d and e, IgG translational start and stop
codons, respectively. The A1 heavy chain coding region was inserted as
a blunt-ended NcoI-EagI fragment into the singular EcoRV site of
pBJ41. The A1 light chain coding region was inserted as a blunt-ended
NcoI-EcoRI fragment into the same site.
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103 PFU of MHV-JHM (corresponding to 200 and 2,000 50% lethal doses,
respectively). Mice were monitored daily for mortality and morbidity.
RESULTS
MHV-JHM infections can be effectively prevented in vitro
and in vivo by neutralizing antibodies, CD41 T cells, and
CD81 T cells (10, 40, 42). The majority of neutralizing anti-
bodies are directed against the viral surface (S) glycoprotein.
MAb A1 (42), which binds to the S1 subunit of the MHV-JHM
S protein, is one of the most potent antibodies with regard to
virus neutralization and the inhibition of virus-induced cell-to-
cell fusion. We have isolated the variable regions of MAb A1
and transferred them into different eukaryotic expression vec-
tors. The recombinantly expressed version of MAb A1 dis-
played the same biological activity as the parental MAb se-
creted from the A1 hybridoma cell line (21, 22). In the studies
described here, the MAb A1 variable regions were linked to
human constant regions of the IgG isotype to facilitate their
identification against the background of murine antibodies.
The resulting chimeric open reading frames were inserted into
a mammary gland-specific expression cassette based on the
ovine b-LG gene (Fig. 1). After confirming expression of the
antibody genes in cell culture (data not shown), the two ex-
pression vectors (pBJ41-A1L and pBJ41-A1H) were used for
the generation of transgenic animals.
In all, eight lines of transgenic mice were generated. The
expression vectors pBJ41-A1L and pBJ41-A1H were microin-
jected together with the b-LG expression construct pSS1tgXS
(1) at a ratio of 1:1:3. This vector is expressed in a copy
number-dependent manner in transgenic animals (43) and has
been shown to increase the expression of colinked transgenes
(4). The molecular basis of this “transgene rescue effect” is not
known, but it is assumed that the b-LG construct is able to
generate independent chromatin domains which escape the
silencing effect of neighboring chromatin structures (4).
Defatted milk of transgenic mothers was analyzed for the
expression of recombinant antibody by Western blotting. To
do this, the human constant regions of the MHV-neutralizing
antibody were detected by using an HRP-linked rabbit anti-
human IgG antiserum. Of the eight transgenic lines transmit-
ting all three transgenes, five expressed the heavy and the light
chains of the recombinant antibody. In two transgenic lines,
only light chain protein but no heavy chain protein was detect-
able (Table 1). The seven lines which expressed the light chain
gene expressed the genomic b-LG construct as well. The light
chain was always expressed in excess of the heavy chain (Ta-
ble 1 and Fig. 2) and is also readily detected in a Coomassie
blue-stained protein gel (data not shown). The transgene copy
number was estimated in seven of the eight lines obtained
(Table 1) and varied from 1 to 10 copies (heavy chain) and 4 to
15 copies (light chain). The transgenes encoding the antibody
light chain and the heavy chain were microinjected into fertil-
ized oocytes at equimolar levels. However, the transgene copy
numbers seem to indicate that consistently more copies of the
light than the heavy chain construct were incorporated into the
host genome. The reason for this is unknown, but it may be due
to a leaky expression of the transgenes during early develop-
mental stages which, in turn, leads to a cytotoxic overproduc-
tion of heavy chain protein and the subsequent loss of embryos.
TABLE 1. Transgene copy number and expressiona
Transgenic line
pSS1tgXS pBJ41-A1H pBJ41-A1L
No. of copies Level of b-LGexpressionb No. of copies
Level of expression and
concn (mg/ml)c No. of copies
Level of expression and
concn (mg/ml)
HEP3 16 1111 2 (1) (,20) 5 1 (40)
HEP10 20 1111 2 (1) (,20) 7 1 (400)
HEP17 NDd ND ND 2 ND (1) (300)
HEP20 12 2 1 2 6 2
HEP30 6 11111 1 (1) (70) 4 1 (800)
HEP36 10 ND 2 2 4 (1) (150)
HEP38 30 11 10 (1) (,20) 15 1 (650)
HEP50 2 11 2 1 (500) 10 11 (2,900)
a Transgene copy number was determined as described in Materials and Methods. Relative levels of transgene expression were determined by Western blotting and
Coomassie brilliant blue protein staining after polyacrylamide gel electrophoresis.
b 1, transgene expression could be detected by Western blotting and protein staining. The number of plus signs indicates the relative level of expression. (1),
transgene expression could be detected by Western blotting but not by protein staining; 2, transgene expression could not be detected by Western blotting.
c The concentration of heavy and light chain protein as quantified by densitometric scanning of Western blots (as described in Materials and Methods).
d ND, not determined.
FIG. 2. Western blot analysis of milk samples. Aliquots of defatted
milk samples (corresponding to 1 ml of milk) isolated from mice of six
transgenic lines were separated by 15% polyacrylamide gel electro-
phoresis alongside a human IgG standard (1,000, 300, and 100 ng of
IgG) and blotted onto nitrocellulose. The human IgG portion of the
chimeric recombinant antibody was detected by using an HRP-linked
rabbit anti-human IgG antiserum. The blot was developed using a che-
miluminescent detection system (Pierce). The positions of the anti-
body chains and the sizes of the molecular marker proteins are indi-
cated.
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No correlation between the transgene copy numbers and the
levels of antibody expression could be detected (Table 1). We
interpret this to indicate that the site of transgene integration
had a dominant effect on gene expression. Although expression
of the light chain protein was consistently higher than expres-
sion of the heavy chain protein, this did not directly correlate
with transgene copy number. Additionally, no correlation
could be detected between the levels of b-LG protein expres-
sion and antibody expression (Table 1).
The concentrations of the heavy and light chain proteins
were quantified by densitometry in comparison to IgG stan-
dards (Beriglobin; pooled human immunoglobulin; Behring-
werke). Maximum levels of 0.5 and 2.9 mg/ml, respectively, of
heavy and light chain proteins were obtained in transgenic line
HEP50. The heavy chain, which comprises 69% of the total
molecular weight of an IgG molecule, can only be secreted
from cells as part of a complete antibody. In contrast, the light
chain protein can be secreted individually. Therefore the 0.5
mg of heavy chain protein per ml measured in the milk of
transgenic line HEP50 corresponds to a total recombinant IgG
concentration of 0.7 mg/ml. The defatted milk of transgenic
line HEP50 was subsequently analyzed in a virus neutralization
assay. A 1024 dilution of defatted milk reduced MHV-JHM
infectivity by 90% (Fig. 3A), which corresponds to 125 pg of
IgG being required to neutralize 1 PFU of MHV-JHM. This is
consistent with results we have obtained in cell culture, where
100 pg of IgG was required to neutralize 1 PFU of MHV-JHM
(21). Milk isolated from nontransgenic mice did not show any
neutralizing effect against the MHV-JHM infection (Fig. 3A).
This confirms the fact that the breeding colony of mice was
seronegative for MHV-JHM and also that the recombinant
antibody is the decisive virus-neutralizing factor in milk. De-
fatted milk samples from four other transgenic lines were also
analyzed by neutralization assays. All of the samples neutral-
ized MHV infectivity, albeit with different levels of efficacy
(Fig. 3B). The dilutions at which MHV-JHM infectivity was
reduced by 90 and 50% were correlated with expression of the
heavy chain (which is the limiting factor for antibody forma-
tion) (Fig. 3C). The linear correlation observed confirms that
the concentration of the recombinant antibody in the milk of
these transgenic animals is the critical factor determining neu-
tralization activity.
Finally, the ability of recombinant antibody secreted in
breast milk to protect suckling mice in vivo was determined.
Transgenic mice and their nontransgenic littermates were in-
fected intranasally with virulent MHV-JHM. Under these con-
ditions (31), 100% of naive mice succumb to acute, fatal en-
cephalitis by 5 to 7 days postinoculation. However, as shown in
Table 2, 23 of 23 suckling mice nursed by transgenic dams did
not develop acute encephalitis, whereas 6 of 6 suckling mice
nursed by transgene-negative animals died by 7 days postin-
fection (Table 2). Infected mice nursed by transgenic dams also
grew at the same rate as uninfected mice nursed by transgenic
FIG. 3. Neutralization assay of milk samples. (A) Dilutions of milk
samples isolated from mice of the transgenic line HEP50 and from a
nontransgenic control mouse were tested in a virus neutralization
assay. The number of syncytia obtained with different milk dilutions
and in the absence of milk is indicated. Each line represents the results
of one experiment. (B) Dilutions of milk samples isolated from mice of
the transgenic lines HEP3, HEP10, HEP30, HEP38, and HEP50 were
tested in a virus neutralization assay. The number of syncytia obtained
with the different dilutions and in the absence of milk is indicated.
Each line represents the results of one experiment. (C) Correlation of
neutralization activity with antibody expression in milk samples from
mice of transgenic lines HEP10, HEP30, HEP38, and HEP50. The
milk dilutions at which MHV-JHM-induced plaque formation is in-
hibited by 50 and 90% were determined by virus neutralization assays
and correlated with expression of the recombinantly expressed MAb
A1 heavy chain protein as determined by densitometric scanning of
Western blots (arbitrary units).
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dams (Fig. 4). In cross-fostering experiments, we showed that
antibody delivery in the breast milk was critical to this protec-
tion. When naive B6 suckling mice were nursed by transgenic
dams, they were also fully protected (n 5 20) from acute
encephalitis (Table 2). Mice were subsequently monitored for
signs of late onset disease caused by chronic demyelination
(31). However, no indicative symptoms could be detected for
as many as 60 days postinoculation, indicating that sufficient
antibody was transferred to the suckling offspring to control
the initial inoculum (31). In other experiments, we showed that
the inoculated mice also did not transmit MHV-JHM to sero-
negative contacts.
Mice from another transgenic line (HEP36), which ex-
presses only minute amounts of recombinant antibody A1 (Ta-
ble 1), were challenged intranasally with MHV-JHM. None of
the offspring of HEP36 dams were protected against the virus
challenge (Table 2). This suggests that transgenesis per se does
not influence the ability of mice to protect their offspring
against MHV-JHM infection.
The protection exerted by the recombinant antibody sup-
plied in milk could be local (inhibiting virus entry via the
oronasal tract) or systemic (preventing infection throughout
the animal after uptake of the antibody through the intesti-
nal mucosa). Antibodies can be taken up as intact proteins
through the gut via specific receptors up to 19 days postpartum
in mice (27). To determine whether the protection is systemic,
offspring suckling HEP50 dams were challenged by intracere-
bral inoculation of 700 PFU (n 5 5) or 7,000 PFU (n 5 4) of
MHV-JHM (corresponding to 50% lethal doses of 200 and
2,000, respectively). All mice survived the challenge without
sign of disease. This suggests that the recombinant antibody
provides a strong systemic protection, although additional local
effects may also occur. Moreover, these results suggest that the
chimeric, recombinant antibody carrying human constant re-
gions is successfully transported across the gut epithelium and
to and across the blood-brain barrier. These results also indi-
cate that the recombinant antibody is able to exert its protec-
tive activity in the absence of other milk components (for
example, complement) that may have specifically or nonspe-
cifically bound to it.
DISCUSSION
Milk-borne antibodies have been shown to be an efficient
means of preventing infectious disease in mammals (5, 6, 8, 11,
17, 18). Synthesis of maternal neutralizing antibodies can be
induced by vaccines or natural infections. In some instances
(e.g., if vaccination is ineffective or if infection with live patho-
gens results in high mortality), alternative routes have to be
employed to provide passive immunization to mammalian off-
spring. Purified neutralizing MAbs can be injected into preg-
nant or lactating host animals (5) or directly administered to
neonates (2, 38). In order to generate milk which contains
antibodies of therapeutic value, animals which are not the
natural host (preferably ruminants, which yield large amounts
of milk) can be immunized with live pathogens (7, 17).
We have analyzed whether expressing a neutralizing anti-
body as a recombinant protein in the milk of transgenic ani-
mals may provide an alternative to these procedures. This
transgenic approach is particularly useful if (i) no useful vac-
cines are available, (ii) neutralizing antibodies are a major
component of the host’s defense against the pathogen in ques-
tion, and (iii) the period during which the infection is life-
threatening is limited. The use of transgenic animals offers the
additional advantage that the most potent antibodies can be
selected by in vitro analyses before transgenes are established
from the respective hybridoma cell lines. Moreover, no live
pathogens have to be introduced into an animal colony. Coro-
naviruses, which cause diseases of economic importance in
animals and humans, fulfill all of the above-mentioned criteria.
Therefore, transgenic animals that express neutralizing anti-
bodies in the milk may, in the long term, provide a strategy to
protect animals during the suckling period. The experiments
described here demonstrate that this approach is practicable.
However, antibody isotypes mediating lactogenic immunity
vary between different species (27). There are also profound
differences in the intestinal uptake of immunoglobulins (27).
Transgene-mediated strategies manipulating lactogenic immu-
nity in livestock will therefore have to be adapted to the re-
quirements of individual species in terms of immunoglobulin
isotype and expression strategy. In that respect, the transgenic
mouse-MHV model provides an excellent opportunity to de-
termine the critical factors for successful immune protection
through in vivo challenge experiments.
Two features distinguish transgene-mediated lactogenic im-
munity from the natural process of passive immunization by
FIG. 4. Weight gain in infected and control animals. MHV-JHM-
infected mice (n 5 23, 12 females and 11 males) nursed by HEP50-
positive transgenic dams and noninfected control mice (n 5 20, 11
females and 9 males) were weighed at 44 days of age (34 days postin-
fection). Mean values and standard deviations are shown.
TABLE 2. MHV-specific antibody in breast milk protects
mice from acute encephalitisa
Dams (litters) Offspring (no.) % Mortality
HEP50[1] (3) HEP50[1] 3 B6 (23) 0
HEP50[2] (1) HEP50[2] 3 B6 (6) 100
HEP50[1] (3) B6 3 B6 (20) 0
HEP36[1] (2) HEP36[1] 3 B6 (8) 100
a Transgenic mice are designated HEP50[1] and HEP36[1]. B6 mice are
nontransgenic control mice. Nontransgenic littermates of HEP50[1] mice are
designated HEP50[2]. Offspring from transgenic mice (HEP50[1] and HEP36
[1] females mated with B6 males), nontransgenic mice (HEP50[2] females
mated with B6 males) and naive B6 mice were challenged intranasally with
MHV-JHM as described in Materials and Methods. Mortality was monitored in
the indicated number of litters of suckling mice nursed by transgenic (HEP50[1],
HEP36[1]) or nontransgenic (HEP50[2]) dams.
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maternal antibodies. In the natural situation, newborn animals
are provided with a polyclonal mixture of antibodies against a
particular pathogen. The transgenic dams described here only
provide a single, albeit highly neutralizing, antibody to their
offspring. As has been shown previously, the b-LG-based ex-
pression system is able to supply immunoglobulin at a high
concentration throughout the entire lactation period (39). In
mammals, the total immunoglobulin concentration in co-
lostrum ranges between 5 mg/ml (rat) and 250 mg/ml (cow).
Lower immunoglobulin levels, ranging from 1 mg/ml (human)
up to 10 mg/ml (pig), are found in milk (27, 41). Therefore, the
concentration of recombinantly expressed neutralizing anti-
body of 0.7 mg/ml exceeds the concentration of any single
monospecific antibody present in milk by some orders of mag-
nitude. Nevertheless, there appeared to be no selection of virus
escape mutants, which could overcome the immune protection
and lead to overt disease within the time frame of the exper-
iment. This indicates that production of a single MHV-JHM
neutralizing antibody in milk is sufficient to provide full pro-
tection during the suckling period.
Milk proteins and their derivatives have been shown to have
antibacterial and antiviral effects (29, 34, 44). In our experi-
mental model, the neutralizing effect of the mouse milk sam-
ples was dependent on the concentration of the recombinant
antibody. This suggests that no other natural components of
milk provide a protective effect against MHV-JHM infections.
The levels of antibody production and secretion into milk
are critical factors for the establishment of transgene-mediated
virus resistance. The concentration of 0.7 mg of mature IgG
per ml is at the lower end of expression levels that have been
previously reported for other recombinant antibodies ex-
pressed in the milk of transgenic mice (0.4 mg/ml [28], 0.8
mg/ml [30], 4 mg/ml [13], 5 mg/ml [3], and 6 mg/ml [39]).
Nevertheless, complete protection of litters suckling transgenic
dams could be obtained at these expression levels. The com-
parably low expression level is at least in part due to the failure
to produce equimolar amounts of heavy and light chain protein
(compare Table 1 and Fig. 2). This confirms our previous
experiences with cell culture (21) and data published by others
(33, 44). The consistent excess of light chain protein over heavy
chain protein is due to the cytotoxicity of unpaired heavy
chains (19), which leads to the death of cells in which the heavy
chain is overexpressed. Additionally, we found that the MAb
A1 heavy chain transgene was present at a lower copy number
than the MAb A1 light chain construct in all strains of mice
analyzed. This is consistent with the findings of Sola and col-
leagues (39), who used a b-LG-based expression system to
express a recombinant antibody that neutralizes the porcine
coronavirus transmissible gastroenteritis virus in the milk of
transgenic mice. In contrast, when an expression system based
on the whey acidic protein (WAP) promoter was used to ex-
press IgG-encoding genes, most of the transgenic lines gener-
ated carried an excess of heavy chain expression constructs (3).
One possible explanation is that the b-LG promoter is active at
an early stage of development and causes the loss of embryos
in which the (cytotoxic) heavy chain is overexpressed. Trans-
genic animals in which the two antibody chains are expressed
in equimolar amounts can be generated by microinjection (33)
but may require the screening of a larger number of transgenic
lines.
In conclusion, we have demonstrated that high levels of a
virus-neutralizing antibody can be generated in the milk of
transgenic mice and that full protection against virus-induced
disease can be accomplished in newborn animals via this route.
Thus, in the murine system, we have established a proof of
principle, and the application of this technology to generate
virus-resistant animals can now be pursued. Additionally, it
now seems feasible that ruminants could be modified by trans-
genic methodology to produce milk containing neutralizing
antibodies directed against pathogens responsible for major
human infant diseases.
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